Like most CROs, Parexel International relies on Big Pharma for most of its service revenue. But the recent explosion in biotech IPOs and venture capital deals has put a lot of money in the hands of small drugmakers, and that's changing the approach for the industry's largest contractors, a company exec said.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
German contract researcher Evotec has signed a deal with Medicines for Malaria Venture, lending its expertise to the nonprofit's efforts to encourage neglected disease R&D around the world.
Durham, NC's Clinverse has put together a $9.1 million C round, raising cash to support its technology for managing costs in clinical trials.
Biotech Otologic Pharmaceuticals has chosen North Carolina's PharPoint Research to run an early trial of its lead candidate, a treatment for hearing loss.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.
WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.
From Our Sister Sites
Mobile medical app provider AirStrip reeled in $25 million in strategic capital to beef up its product offerings and develop its innovative health monitoring system for smartphones.
Cenix BioScience GmbH, a leading preclinical contract research provider and technology developer specialized in genome-scale gene modulation studies and high throughput, high content pharmacology,...